This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Neurocrine Biosciences (NBIX) - FREE Research Report

Gorman Kevin Charles who is President and CEO at Neurocrine Biosciences sold 3,750 shares at $18.57 on Jan. 13, 2014. Following this transaction, the President and CEO owned 180,952 shares meaning that the stake was reduced by 2.03% with the 3,750-share transaction.

OBrien Christopher Flint who is Chief Medical Officer at Neurocrine Biosciences sold 6,750 shares at $18.88 on Jan. 13, 2014. Following this transaction, the Chief Medical Officer owned 96,544 shares meaning that the stake was reduced by 6.53% with the 6,750-share transaction.

Coughlin Timothy P who is Chief Financial Officer at Neurocrine Biosciences sold 1,750 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Financial Officer owned 97,874 shares meaning that the stake was reduced by 1.76% with the 1,750-share transaction.

Bozigian Haig P. who is Chief Development Officer at Neurocrine Biosciences sold 1,625 shares at $18.58 on Jan. 13, 2014. Following this transaction, the Chief Development Officer owned 78,579 shares meaning that the stake was reduced by 2.03% with the 1,625-share transaction.

Grigoriadis Dimitri E. who is Chief Research Officer at Neurocrine Biosciences sold 1,625 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Research Officer owned 77,058 shares meaning that the stake was reduced by 2.07% with the 1,625-share transaction.

Gano Kyle who is Chief Business Dev Officer at Neurocrine Biosciences sold 1,250 shares at $18.57 on Jan. 13, 2014. Following this transaction, the Chief Business Dev Officer owned 23,738 shares meaning that the stake was reduced by 5% with the 1,250-share transaction.

The shares most recently traded at $19.10, up $0.53, or 2.77% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 4-Week # shares sold: 233,000
  • 12-Week # shares sold: 233,000
  • 24-Week # shares sold: 315,531

The average volume for Neurocrine Biosciences has been 1.0 million shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 99.68% year-to-date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 11 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs